Adempas approved to treat pulmonary hypertension

(HealthDay)—Adempas (riociguat) has been approved by the U.S. Food and Drug Administration to treat two types of pulmonary hypertension, characterized by high blood pressure in the arteries of the lungs.

The chronic, disabling disease forces the heart to work harder than usual, and can lead to death or the need for a lung transplant, the FDA said in a news release.

Adempas, among a class of drugs called soluble guanylate cyclase stimulators, relaxes the arteries. This increases blood flow and eases , the agency said.

The drug was approved for people with chronic thromboembolic (CTEPH) after surgery, or for people who cannot have surgery, to help improve the ability to exercise. The drug also was approved for people with (PAH) of various causes.

Adempas was evaluated in a clinical study involving 261 people with CTEPH. People who were treated with the drug were able to walk about 150 feet further in six minutes after 16 weeks of treatment than people who took a placebo, the FDA said.

In another trial of 443 people with PAH, people treated with the drug were able to walk about 118 feet further in six minutes than those who had been treated with a placebo.

The most common side effects of the drug included headache, dizziness, indigestion, tissue swelling, nausea and vomiting.

Adempas' label includes a boxed warning that pregnant women shouldn't use the drug, which can harm a growing fetus, the agency said.

The is marketed by Wayne, N.J.-based Bayer HealthCare Pharmaceuticals.

More information: The FDA has more about this approval.

add to favorites email to friend print save as pdf

Related Stories

Pomalyst approved for advanced multiple myeloma

Feb 09, 2013

(HealthDay)—Pomalyst (pomalidomide) has been approved by the U.S. Food and Drug Administration to treat cases of multiple myeloma that have not responded to other therapies.

New drug approved to treat HIV-1

Aug 13, 2013

(HealthDay)—Tivicay (dolutegravir) has been approved by the U.S. Food and Drug Administration to treat infection with HIV-1, a strain of the virus that causes AIDS.

Iclusig approved for rare leukemias

Dec 16, 2012

(HealthDay)—Iclusig (ponatinib) has been approved by the U.S. Food and Drug Administration to treat two rare forms of leukemia..

Recommended for you

Supercomputers link proteins to drug side effects

Oct 20, 2014

New medications created by pharmaceutical companies have helped millions of Americans alleviate pain and suffering from their medical conditions. However, the drug creation process often misses many side ...

No added benefit proven for umeclidinium/vilanterol in COPD

Oct 20, 2014

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

User comments